Stockscreener 앱 받기
6.53
2.10%
-0.14
시간 외 거래:
6.51
-0.02
-0.31%
Amicus Therapeutics Inc 주식(FOLD)의 최신 뉴스
Pompe Disease Market Expected to Experience Major Growth - openPR.com
Voya Investment Management LLC Sells 743,492 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Aquatic Capital Management LLC - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by PDT Partners LLC - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Tower Research Capital LLC TRC - MarketBeat
Amicus Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Marshall Wace LLP Boosts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Dark Forest Capital Management LP Purchases Shares of 38,148 Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS Raises Price Target for Amicus Therapeutics (FOLD) to $22, M - GuruFocus
Amicus Therapeutics (FOLD) Target Price Lowered by Goldman Sachs | FOLD Stock News - GuruFocus
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls - TradingView
UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Dise - GuruFocus
UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Disease Outlook | FOLD Stock News - GuruFocus
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Adjusts Amicus Therapeutics Price Target to $22 From $21, Maintains Buy Rating - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Dimerix and Amicus to commercialise DMX-200 in US - MSN
Amicus Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0.07 - GuruFocus
Dimerix strikes $601M Amicus deal for kidney disease drug DMX-200 - BioWorld MedTech
Dimerix and Amicus Therapeutics Announce Exclusive License Agree - GuruFocus
Amicus Therapeutics Turns to Non-GAAP Q1 Earnings, Revenue Rises; Shares Down - marketscreener.com
Earnings call transcript: Amicus Therapeutics reports Q1 2025 loss, stock drops - Investing.com India
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates - Yahoo Finance
Amicus Therapeutics: Q1 Earnings Snapshot - San Antonio Express-News
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates - The Manila Times
Amicus Therapeutics Q1 2025 slides: 15% revenue growth, new kidney disease program - Investing.com
Amicus (FOLD) Shows Strong Revenue Growth Amid Recent Quarter Ch - GuruFocus
BRIEF-Amicus Therapeutics Q1 Revenue USD 125.2 Million Vs. IBES Estimate USD 135.9 Million - TradingView
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.75 - MarketBeat
Amicus Therapeutics Signs Exclusive License Deal for Dimerix Kidney Disease Therapy - marketscreener.com
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States - GlobeNewswire
Amicus Therapeutics Q1 2025 Earnings Preview - MSN
Amicus Therapeutics Earnings Preview - Nasdaq
Fabry Disease Market: Epidemiology, Drugs, Companies, DelveInsight | Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeuti - The Globe and Mail
LATAM Fabry Disease Market Set to Witness Significant Growth - openPR.com
Amicus Therapeutics (FOLD) to Release Earnings on Thursday - MarketBeat
Russell Investments Group Ltd. Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Rock Springs Capital Management LP Purchases 1,349,145 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Jump Financial LLC Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Report Q1 Earnings: What's in the Cards? - MSN
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Is Amicus Therapeutics, Inc. (FOLD) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
0.39%
3.66%
자본화:
|
볼륨(24시간):